| Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1–infected patients: the MaxCmin1 Trial UB Dragsted, J Gerstoft, C Pedersen, B Peters, A Duran, N Obel, ... The Journal of infectious diseases 188 (5), 635-642, 2003 | 148 | 2003 |
| Enfermedad crónica en adultos mayores A Durán, L Valderrama, AF Uribe, A González, JM Molina Universitas médica 51 (1), 16-28, 2010 | 117 | 2010 |
| A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial MaxCmin2 trial group, UB Dragsted, J Gerstoft, M Youle, Z Fox, M Losso, ... Antiviral therapy 10 (6), 735-743, 2005 | 95 | 2005 |
| Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis AS Duran, MH Losso, H Salomón, DR Harris, S Pampuro, ... Aids 21 (2), 199-205, 2007 | 39 | 2007 |
| Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries M Gomez-Carrillo, S Pampuro, A Duran, M Losso, DR Harris, JS Read, ... AIDS Research & Human Retroviruses 22 (11), 1186-1191, 2006 | 37 | 2006 |
| Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs LE Soto-Ramirez, R Rodriguez-Diaz, AS Durán, MH Losso, H Salomón, ... AIDS research and human retroviruses 24 (6), 797-804, 2008 | 30 | 2008 |
| Use of third line antiretroviral therapy in Latin America C Cesar, BE Shepherd, CA Jenkins, M Ghidinelli, JL Castro, VG Veloso, ... PLoS One 9 (9), e106887, 2014 | 22 | 2014 |
| El Concepto de Medio Rural: Dificultades y Perspectivas FJ Castellano, J Castro, A Durán Revista Espacios 40, 14, 2019 | 13 | 2019 |
| Increasing trends in primary NNRTI resistance among newly HIV1diagnosed individuals in Buenos Aires, Argentina N RodriguezRodrigues, A Duran, MB Bouzas, I Zapiola, M Vila, D Indyk, ... African Journal of Reproduction and Gynaecological Endoscopy 16 (1), 2013 | 13 | 2013 |
| Clinical and demographic factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection in adults: a secondary cross-protocol analysis of 4 randomized clinical trials DA Theodore, AR Branche, L Zhang, DS Graciaa, M Choudhary, ... JAMA network open 6 (7), e2323349-e2323349, 2023 | 11 | 2023 |
| Prevention of mother to child HIV transmission AS Duran, SA Ivalo, A Hakim, FM Masciottra, R Zlatkes, L Adissi, ... MEDICINA-BUENOS AIRES- 66 (1), 24, 2006 | 9 | 2006 |
| Conocimientos, actitudes y prácticas en VIH y Salud Sexual y Reproductiva (SSR) y uso de tecnologías de la información y la comunicación (TIC) entre adolescentes de Argentina L Wang, MVFHMJ Ravalli, A Durán UNICEF Argentina, 2012 | 7 | 2012 |
| Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: the MaxCmin1 trial U Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, A Duran, ... Ninth European AIDS Conference, Warsaw, Poland, 2003 | 7 | 2003 |
| Risk of COVID-19 after natural infection or vaccination AM Rick, MB Laurens, Y Huang, C Yu, TCS Martin, CA Rodriguez, ... EBioMedicine 96, 2023 | 6 | 2023 |
| Temática Digital: gestión educativa. Reflexiones del tema: Algunas consideraciones sobre la administración universitaria en el contexto del proceso de municipalización de la … M Vidal, A Durán, N Pujals Educ Med Super 22 (2), 2008 | 6 | 2008 |
| El uso de las nuevas tecnologías en los centros educativos: realidad o ficción AS Duran Congreso Internacional Virtual y Presencial sobre el Profesorado ante el …, 2005 | 6 | 2005 |
| Cintura e índice de masa corporal: los mejores predictores antropométricos en la reducción y progresión de la agregación de factores de riesgo cardiometabólicos G Valentino, MJ Bustamante, S Durán Agüero, L Orellana, M Adasme, ... Archivos Latinoamericanos de Nutrición 67 (3), 200-210, 2017 | 5 | 2017 |
| Respuesta al VIH/SIDA en Argentina A Duran, C Bloch Revista Argentina de Salud Pública 1 (1), 38-40, 2009 | 5 | 2009 |
| The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir … UB Dragsted, J Gerstoft, M Youle, A Duran, DT Jayaweera, A Rieger, ... 6th International Congress on Drug Therapy in HIV Infection, 17-21, 2002 | 5 | 2002 |
| Safety and efficacy evaluation of a phase IV randomized, open-label, multicentre trial of indinavir/ritonavir (800/100 mg bid) vs. saquinavir/ritonavir (1000/100 mg bid) in … P Cahn, UB Dragsted, N Obel 14th World AIDS Conference. Barcelona, 2002 | 4 | 2002 |
